

Material Information (3176 MEDIGEN)

SEQ_NO	1	Date of announcement	2025/12/09	Time of announcement	17:47:52
Subject	Announcement of Important Resolution by the Board of Directors of Subsidiary Medic Vision AI Limited				
Date of events	2025/12/09	To which item it meets	paragraph 10		

1.Date of occurrence of the event:2025/12/09
2.Counterparty to the contract or commitment:Centre for Eye Research Australia Limited
3.Relationship with the Company:None
4.Starting and ending dates (or rescission date) of the contract or commitment:From the date hereof until the date of execution of the formal agreement.
5.Major content (not applicable where rescinded):
The Company's important subsidiary, Medic Vision AI Limited (formerly known as TGB Diagnostics Limited), plans to establish a joint venture company with Centre for Eye Research Australia Limited (hereinafter "CERA"), the leading ophthalmic research centre in Australia. The joint venture company will obtain CERA's gene therapy technologies and will be dedicated to the development of gene therapy drug for Inherited Retinal Disease ("IRD").

The board of directors of Medic Vision AI Limited has authorized the Chairman to execute a term sheet for the proposed joint venture. Subject to acquiring 50% equity ownership in the new company, the Chairman is authorized to negotiate the transaction details and execute all documents necessary for the completion of the transaction.

6.Restrictive covenants (not applicable where rescinded):none
7.Commitment (not applicable where rescinded): none
8.Any other important agreement (not applicable where rescinded): none
9.Effect on company finances and business:
The term sheet for the proposed joint venture merely sets forth the intentions and mutual understanding of the parties and, as of the date hereof, has not had any material impact on the subsidiary's financial position or business operations.
10.Concrete purpose/objective:
To acquire gene therapy technologies and thereby strengthen the subsidiary's strategic positioning in the ophthalmic pharmaceutical field.
11.Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 8 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.):
(1) Medic Vision AI Limited, formerly known as TGB Diagnostics Limited, is a subsidiary established by the Company in Australia. The company officially changed its name to Medic Vision AI Limited in October 2025.
(2)The development of new drugs takes a long time, involves high investment costs and there is no guarantee of success. This may expose investment to risks and investors should exercise due diligence and invest with caution.